Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV002263345 | SCV002544877 | likely benign | not provided | 2022-04-01 | criteria provided, single submitter | clinical testing | WDFY3: PP2, BS2 |
Revvity Omics, |
RCV003138135 | SCV003823688 | uncertain significance | Microcephaly 18, primary, autosomal dominant | 2020-11-02 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003365722 | SCV004065018 | uncertain significance | Inborn genetic diseases | 2023-07-14 | criteria provided, single submitter | clinical testing | The c.9304G>A (p.V3102M) alteration is located in exon 61 (coding exon 58) of the WDFY3 gene. This alteration results from a G to A substitution at nucleotide position 9304, causing the valine (V) at amino acid position 3102 to be replaced by a methionine (M). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |